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Using polymerase chain reactions and genome walking strategies, adeno-associated virus (AAV)-like capsid genes were isolated from rat and
mouse liver genomic DNA, where they are present at <5 copies per cell. These genes define two new species of AAVs since their amino acid
sequences are <60% identical to each other or to any other AAV capsid. They are most similar to the AAV-5 and goat AAV capsids. A recombinant
vector with the mouse AAV capsid and a lacZ transgene (rAAV-mo.1 lacZ) was able to transduce rodent cell lines in vitro. However, it was not
able to transduce eight human cell lines or primary human fibroblasts in vitro. It did not bind heparin and its ability to transduce cells in vitro was
not inhibited by heparin, mucin, or sialic acid suggesting it uses a novel entry receptor. rAAV-mo.1 lacZ was 29 times more resistant to in vitro
neutralization by pooled, purified human IgG than AAV-2. In vivo, rAAV-mo.1 lacZ efficiently transduced murine ocular cells after a subretinal
injection. Intramuscular injection of a rAAV-mo.1 human factor IX (hFIX) vector into mice resulted in no detectable hFIX in plasma, but
intravenous injection resulted in high plasma levels of hFIX, equivalent to that obtained from a rAAV-8 hFIX vector. Biodistribution analysis
showed that rAAV-mo.1 primarily transduced liver after an intravenous injection. These AAV capsids may be useful for gene transfer in rodents.
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Adeno-associated viruses are nonenveloped parvoviruses
belonging to the Dependovirus genus (Grimm and Kay, 2003).
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doi:10.1016/j.virol.2006.05.023about 5000 nucleotides that encode two genes called rep and
cap. The rep gene encodes 4 proteins that play roles in viral
DNA replication, DNA packaging, and the regulation of
transcription and splicing. The cap gene encodes three capsid
proteins (VP1, VP2, VP3) that multimerize at an average ratio
of about 5:5:50, respectively, in a complete capsid that contains
60 capsomeres. The capsid proteins package viral DNA,
determine viral tropism, and are the target for neutralizing
antibodies. The capsid proteins are produced from the same
translational reading frame as a result of alternative splicing and
use of an alternative translation initiation site. VP1 is translated
from a minor spliced RNA and is about 730 amino acids long.
The N-terminal domain of VP1 is located inside the assembled
capsid (Kronenberg et al., 2005) and encodes a phospholipase
A2 that is required for transduction in vitro (Girod et al., 2002).
Translation of VP2 initiates at an alternate initiation codon
(ACG in many AAVs). VP2 is about 135 amino acids shorter
Fig. 1. Strategy for isolation of rodent AAV rep and capsid genes. (A) A
typical AAV genome structure with inverted terminal repeats (ITRs), and rep
and capsid genes is shown. Primers corresponding to conserved sequences in
a putative multimerization domain in rep (James et al., 2003) and one of
several putative DNA-binding domains (see Materials and methods) in capsid
were used to isolate a 1.5 kbp DNA containing the N-terminus of the AAV-
mo.1 and AAV-ra.1 capsid genes. The rest of the AAV-mo.1 (B) and AAV-
ra.1 (C) capsid sequences were isolated by using a genome walking strategy
as described in Materials and methods. The locations and lengths of each
walking step are indicated.
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dispensable for most functions (Warrington et al., 2004).
Translation of VP3 occurs from a major, spliced RNA at an
AUG codon. VP3 is about 65 amino acids shorter than VP2 at
the amino terminus.
AAVs have been used as gene delivery vectors in animals
and humans for a variety of reasons (Buning et al., 2004; Daly,
2004; Flotte, 2004; Stilwell and Samulski, 2003). Vectors have
been generated that lack all viral genes and can be produced in
the absence of helper viruses or wild type AAV contamination
(Matsushita et al., 1998). They can infect a wide range of cell
types, including nondividing cells. AAVs typically infect a
variety of mammals so that the same vector used in animal
models of disease can be used in human clinical trials. AAVs are
not known to be pathogenic in any human or animal. Although
recombinant AAV (rAAV) genomes can integrate into genomic
DNA at a very low frequency, most transgene expression
appears to come from episomal and not integrated forms, adding
to its favorable safety profile. Expression of transgenes
delivered by rAAV vectors to cells that divide infrequently
can be stable in animals for years. Finally, AAV vectors can be
produced at high levels, are readily purified by scalable methods
and are exceptionally stable over a wide range of physical and
chemical conditions. These properties are compatible with
pharmaceutical development and commercialization. To date,
29 human gene therapy protocols that use AAV have been
submitted to the Office of Biotechnology Activities for review
(http://www4.od.nih.gov/oba/rac/PROTOCOL.pdf).
Gene transfer in rodents using primate-derived AAVs has
been used to model the treatment of various human diseases.
Therefore, it could be useful to have AAVs that are derived from
rodent species such as rat or mouse. One goal of this study was
to isolate functional AAV capsid genes from rodents that might
mediate more efficient gene transfer or display new tropisms.
We isolated 2 rodent AAV-like capsid genes from rat and mouse
liver genomic DNA that are significantly different from primate
AAVs and characterized their properties. The existence of
rodent AAVs in any form has not been reported previously.
Results
Isolation of rodent AAV rep and capsid genes
Primers were designed (Fig. 1A) that correspond to
conserved amino acid sequences in a putative multimerization
domain (James et al., 2003) of AAV rep (VPFYGCVNWT-
NENF) and one of several conserved, putative DNA-binding
domains (see Materials and methods) of AAV capsid
(GVGNASGNWHCDS). PCR with these primers resulted in
amplification of 1.5 kbp products using rat and mouse liver
genomic DNA as templates. Sequencing of these DNA
fragments revealed that they had homology to AAV rep and
capsid genes but were different from any other known AAV
sequences. These sequences define two new AAV-like species
with highest sequence homology to the Dependovirus genus.
Therefore, the rat AAV-like species was named rat AAV-1, and
the isolate reported here was named AAV-ra.1. The mouseAAV-like species was named mouse AAV-1, and the isolate
reported here was named AAV-mo.1.
Attempts to isolate the remainder of the AAV-ra.1 and
AAV-mo.1 genomes using a variety of inverse PCR methods
and primers located in the rep and capsid genes failed,
possibly due to inefficient amplification across GC-rich ITRs
or the absence of episomal forms. Strategies utilizing rolling
circle replication, which could replicate across ITRs but would
depend on the presence of episomal forms, were also
unsuccessful. We were most interested in studying new
AAV capsids. Therefore, a genome walking method that
uses annealing controlled primers was used to isolate
successive adjacent fragments of the AAV-mo.1 (Fig. 1B)
and AAV-ra.1 (Fig. 1C) capsid genes. Annealing controlled
primers have 6 inosines near the 3′ end that restrict
hybridization to the 3′ end of a primer, thereby reducing
nonspecific hybridization to other parts of the primer. As such,
they allow short sequences at the 3′ end of the primer to be
used to target desired sequences and longer sequences at the
5′ end to allow a secondary amplification.
About 1400 bp of the AAV-mo.1 and the AAV-ra.1 capsid
genes were obtained in the first genome walk. In the second
genome walk, 550 bp of the AAV-mo.1 capsid gene and 397 bp
of the AAV-ra.1 capsid gene were obtained. In the third genome
walk 296 bp of the AAV-mo.1 capsid gene and 360 bp of the
AAV-ra.1 capsid gene were obtained.
Separate strategies were used in the third walk to isolate
the C-terminal sequences of each capsid. After the second
walk on the AAV-mo.1 capsid gene, the primers in genome
walking kit did not amplify any PCR products, possibly
because a target for hybridization to the 3′ end of the primers
Fig. 2. Taxonomic relationship between rodent and other AAV capsid amino
acid sequences. Only those AAV capsids that are most closely related to the
AAV-mo.1 and AAV-ra.1 capsids are shown. AAV-rh.32, 33, and 34 are
described by Gao et al. (2004). AAV-co.2 and AAV-co.3 are AAV capsid genes
we isolated from bovine adenovirus stocks that are less than 5 amino acids
different from the bovine AAV (BAAV) capsid described by Schmidt et al.
(2004). AAV-go.1 is a goat-derived AAV capsid described by Arbetman et al.
(2005). Snake AAV-1 was described by Farkas et al. (2004). Avian AAV was
described by Bossis and Chiorini (2003), AAV-ch.1 is a chicken-derived AAV
capsid described by Estevez and Villegas (2004), and AAV-ch.2 is a capsid we
isolated from chicken liver genomic DNA.
70 M.A. Lochrie et al. / Virology 353 (2006) 68–82(5′-GGTC-3′) does not exist in the remaining sequence of
AAV-mo.1 genome, i.e., the sequence between the end of the
second genomic walk through the end of the inverted
terminal repeat (ITR), assuming AAV-mo.1 exists as a single
integrated copy in mouse genomic DNA. If AAV-mo.1 exists
as a circular episome then a target for the annealing
controlled primers in the SpeedUp kit should have been
present (e.g., at the ends of the sequences obtained in the first
walk). However, in order for the annealing controlled kit
primers to amplify the C-terminal sequence from episomal
targets, PCR may have to occur across an ITR, which in
other AAVs is known to be very inefficient as a result of
their high GC content and extensive secondary structure.
Also the length of such a PCR product could be several
kilobases long and may amplify inefficiently. To circumvent
these problems, we assumed a polyadenylation signal would
be present at the end of the AAV-mo.1 capsid gene as it is
for all other known AAVs. Annealing controlled primers
were designed that would target a canonical AATAAA
polyadenylation signal. This canonical poly A signal is found
after 100% of the 140 AAV capsid genes that were known to
exist at the time these primers were designed. In addition
since all of the poly A signals after those AAV capsid genes
are preceded by a C we added a G to the 3′ end of the
primer. Using these primers, the rest of the AAV-mo.1 capsid
gene and the 3′ untranslated region up to a presumed
polyadenylation signal was isolated.
A variety of primers did not amplify the remaining portion
of the AAV-ra.1 capsid gene including genome walking kit
primers targeted to 5′-GACC-3′ sequences, primers targeted to
4 different polyadenylation signals (CAATAAA, AATAAA,
ATTAAA, and TANA), primers targeted to rep binding sites
(GAGC) in the AAV-2 ITR, annealing controlled primers
targeted to the leucine-stop codons (CTG-TAA) that end most
AAV capsids, multiple primers based on the sequence of the
3′ untranslated region of the AAV-mo.1 capsid gene, and
annealing controlled primers randomized at the last 5 bases
(NNNNN). Therefore, primers were designed that would be
able to hybridize to the last 18 or 27 nucleotides of 140
known AAV capsid genes. Inosines were introduced where
possible to reduce the degeneracy of the primers. These
primers also included a TAA stop codon which terminates
translation of all AAV capsids, except for two snake AAV
capsids. Both of these primers amplified the C-terminal end of
the AAV-ra.1 capsid sequence. The last 6 amino acids of the
C-terminus (YPTRPP), amplified by the shorter 3′ primer,
match known AAV capsid sequences well. However, since the
primer may have been mismatched to the template, there is no
guarantee that is the actual sequence of the C-terminus of the
AAV-ra.1 capsid.
Full-length AAV-mo.1 and AAV-ra.1 capsid genes were
isolated from mouse and rat liver DNA, respectively, using
primers corresponding to the N-terminal and C-terminal ends of
the coding regions. Their sequences showed that the fragments
isolated by genome walking were colinear and not isolated from
contaminants or different rodent AAVs. The NCBI accession
numbers for the AAV-ra.1 rep and capsid genes and the AAV-mo.1 rep and capsid genes are DQ100363 and DQ100362,
respectively.
Taxonomic relationship of rodent capsids to other AAV capsids
A taxonomic tree was constructed by comparing 174
complete and 9 partial AAV capsid sequences. As shown in
Fig. 2, the AAV-ra.1 and AAV-mo.1 capsids are most closely
related to the AAV-5 group (which includes AAV-Go.1) and
more distant from the AAV-4 group (which includes 3 bovine
AAVs and 3 AAVs from rhesus macaques) and the reptilian
AAV group (which includes snake AAV-1 and 3 avian AAVs).
All of these AAVs are more distantly related to other primate-
derived AAVs which includes the AAV-1/6, AAV-2, AAV-2/3
hybrid, AAV-3, AAV-7, and AAV-8/9 groups (Gao et al., 2004).
Amino acid and nucleotide sequences of rodent AAV capsids
Table 1 shows the amino acid and nucleotide sequence
identities between the capsids of AAV-mo.1, AAV-ra.1, and
other representative AAVs from each AAV clade. The AAV-ra.1
and AAV-mo.1 capsid amino acid sequences are less than 60%
identical to any other AAV capsid. Notably the AAV-mo.1 and
AAV-ra.1 capsid amino acid sequences are only 58% identical
to each other. Therefore, they define 2 new species of AAVs.
The sequence variation between these rodent AAV capsids and
other AAV capsids is spread throughout the entire capsid
sequence, unlike the AAV-Go.1 or clade C AAV capsids in
which sequence diversity is in a localized area and is thought to
be the result of a recombination event. Both are clearly more
related to AAVs in the Dependovirus genus than to other
autonomously replicating parvoviruses since the amino acid
sequence identity of AAV-mo.1 and AAV-ra.1 capsids to
capsids from autonomously replicating rodent parvoviruses,
Table 1
Nucleotide and amino acid identities between rodent and other AAV capsids
AAV-mo.1 AAV-ra.1 AAV-1 AAV-2 AAV-hu.2 AAV-3a AAV-4 AAV-5 AAV-7 AAV-8 AAV-9 Avian Snake
% Amino acid identity
AAV-mo.1 100 58 56 56 56 55 51 53 56 56 56 50 50
AAV-ra.1 58 100 52 52 52 50 46 58 52 52 52 47 48
% Nucleotide identity
AAV-mo.1 100 60 59 58 59 58 56 58 58 59 58 61 53
AAV-ra.1 60 100 60 59 59 58 56 68 60 61 60 60 51
Amino acid sequences of capsids that represent each clade of AAV (Gao et al., 2004) are shown. AAV-1 (GenBank accession NC_002077) represents clade A. AAV-2
(GenBank accession AF043303) represents clade B. AAV-hu.2 (GenBank accession AY530585) is a hybrid between AAV-2 and AAV-3 capsid sequences and
represents clade C. AAV-7 (GenBank accession AF513851) represents clade D. AAV-8 (GenBank accession AF513852) represents clade E. AAV-9 (GenBank
accession AX753250) represents clade F. AAVs that have not been assigned clade designations but represent distinct lineages based on taxonomic analysis include
AAV-3a (GenBank accession NC_001729), AAV-4 (GenBank accession NC_001829), AAV-5 (GenBank accession AF085716), avian AAV (GenBank accession
AY629582), and snake AAV (GenBank accession AY349010). Capsid amino acid sequences within a clade are at least 85% identical to each other.
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20%.
Fig. 3A shows a comparison of the amino acid sequences of
the AAV-mo.1, AAV-ra.1, AAV-2, and AAV-5 capsids. As
found from comparisons of the structures of AAV-2 and several
parvovirus capsids, sequences that are buried and form the
conserved, β-stranded jelly roll motif that forms the structural
framework for all parvovirus capsids are highly conserved (Xie
et al., 2002). Sequences in the AAV-mo.1 and AAV-ra.1 capsids
can be found that are homologous to the phospholipase A2 and
predicted DNA-binding domains of other AAVs, as would be
expected since these domains perform essential functions.
Sequences predicted to be on the internal surface of the AAV-
mo.1 and AAV-ra.1 capsid are also well conserved perhaps
reflecting the fact they perform conserved functions such as
interacting with DNA or the phospholipase A2 domain.
Sequences that are on the external surface are highly variable
which suggests rodent capsids may use unique receptors to
infect cells or may be subjected to different immunological
pressures than other AAV capsids.
Several features of the AAV-mo.1 capsid sequence are
notable. The AAV-mo.1 capsid is shorter than any other AAV
capsid. It is 713 amino acids long compared to other AAV
capsids which are 724–740 amino acids long. This difference in
length is due to deletions in several areas. One of the deleted
areas is located on the external surface at the tip of the “spike”,
as is also the case for AAV-4 (Padron et al., 2005), AAV-5
(Walters et al., 2004), and presumably AAV-Go.1, avian AAVs,
and snake AAVs. Therefore, the AAV-mo.1 capsid would be
expected to have a shorter spike relative to AAV-2 (Xie et al.,
2002).
Translation of the AAV-mo.1 VP2 capsid protein may
initiate with a CUG codon, instead of the usual ACG codon.
Alternate initiation codons are always one base different from
the canonical AUG initiation codon. The codon in AAV-mo.1
that is in the position corresponding to the VP2-initiating
codon found in other AAV capsids is CCA, which is not
known to initiate translation of any gene. On the other hand,
CUG has been reported to serve as a translation initiation
codon for genes such as myc (Schwab et al., 2004). In those
cases, the protein may begin with either methionine orleucine. The location of this CUG codon is 2 codons 5′ to the
highly conserved location of the ACG codons found in other
AAV VP2 sequences. There are no other codons near that
CUG that could be used to initiate translation of VP2. It is
clear AAV-mo.1 VP2 is translated since it can be detected by
Western blotting and SDS-PAGE (Fig. 6A). Another unique
feature of the AAV-mo.1 sequence is the distance from the
stop codon to the poly A signal is longer (32 bp) than for any
other AAV (2–22 bp). Finally, the AAV-mo.1 capsid is not
predicted to have a heparin-binding site (Fig. 3A) that is in a
position analogous to the AAV-2 heparin-binding site (Kern et
al., 2003; Opie et al., 2003). Mutating any one of 5 basic
amino acids in the AAV-2 heparin-binding site to alanine
eliminates heparin binding (Kern et al., 2003; Opie et al.,
2003). AAV-mo.1 has 3 amino acids in equivalent positions
that are different from those in AAV-2, including an arginine
in AAV-2 that is an alanine in AAV-mo.1. Therefore, based
on sequence alignments, it is unlikely AAV-mo.1 binds
heparin unless it has a heparin-binding site located at another
position. One sequence feature that is 100% conserved
between most AAV capsids and the AAV-mo.1 capsid is the
epitope (IGTRYLTR) for the B1 monoclonal antibody
(Wobus et al., 2000). Therefore, it is possible to detect the
AAV-mo.1 capsid on a Western blot (Fig. 5).
With regard to the AAV-ra.1 capsid, its length (734 amino
acids) is closer to that of other AAVs. The AAV-ra.1 capsid is
predicted to lack only 1 amino acid on the spike and thus would
be expected to have a sharp, protruding spike like AAV-2. As
for AAV-mo.1, translation of AAV-ra.1 VP2 may begin at a
CUG codon. AAV-ra.1 capsid is also predicted to lack a
heparin-binding site at a position analogous to the AAV-2
heparin-binding site (Fig. 3A).
Partial nucleotide and amino acid sequences of rodent AAV rep
proteins
Fig. 3B shows an alignment of the partial amino acid
sequences of the AAV-ra.1 and AAV-mo.1 rep proteins. They
are 45% identical over a 104 amino acid length. These
sequences are closest to AAV-5 rep, but the level of identity is
low, about 20%.
Fig. 3. Sequence alignments. (A) The amino acid sequences of the AAV-ra.1 and AAV-mo.1 capsids are shown along with AAV-2, a prototypical AAV, and AAV-5, the
primate capsid that is taxonomically the closest to the AAV-ra.1 and AAV-mo.1 capsids. Translation start sites for VP1, VP2, and VP3 are shown. The VP2 start site for
AAV-2 and AAV-5 (ACG, thr) is known, while the VP2 start sites for AAV-mo.1 and AAV-ra.1 (CUG, leu) are presumed. The last 6 amino acids of the C-terminus of
AAV-ra.1 capsid (lower case) correspond to the sequence of a PCR primer and have not been confirmed. Letters in bold are amino acids that are identical in all 4
sequences. H indicates amino acids in the AAV-2 capsid required for heparin binding. Dashes indicate gaps introduced to obtain optimal sequence alignments.
Underlined sequences correspond to a putative DNA-binding domain used to design the capsid DNA-binding domain primer shown in Fig. 1. (B) Partial amino acid
sequences of AAV-ra.1 and AAV-mo.1 rep. Bold letters indicate identities. (C) Nucleotide sequences at 5′ splice donor. Lower case letters indicate the 5′ boundary of
the intron. (D) Nucleotide sequences between rep and capsid genes, at the 3′ splice acceptor and proximal polyadenylation signal. The extent of the rep and capsid
coding regions is indicated. The poly A signals are underlined and the poly A cleavage sites are in bold letters. Lower case letters indicate the 3′ boundaries of introns.
The downstream sequence element (DSE) identified in AAV-5 is underlined and italicized.
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Fig. 3C shows the locations of the 5′ splice donors in the
AAV-2 and AAV-5 introns, and the predicted location of the 5′
splice donors of the AAV-mo.1 and AAV-ra.1 introns. The
locations of the 5′ splice donors of the AAV-mo.1 and AAV-ra.1
are predicted to be in a location similar to that of AAV-5 which
is different from its location in the AAV-2 intron. This would
predict that the AAV-mo.1 and AAV-ra.1 introns are more
similar in length to the shorter intron found in AAV-5 compared
to the intron in the other primate AAVs that are similar to AAV-
2. However, the locations of the 3′ splice acceptor sites in the
AAV-mo.1 and AAV-ra.1 intron are predicted to be identical to
that of AAV-2 and AAV-5 (Fig. 3D).
Fig. 3D shows the nucleotide sequences near the C-terminus
of AAV-mo.1, AAV-ra.1, AAV-2, and AAV-5 rep. Like AAV-5
(Qiu et al., 2004) and unlike AAV-2, AAV-mo.1 and AAV-ra.1
appear to have polyadenylation signals and sites that are entirely
within the rep coding region. AAV-mo.1 and AAV-ra.1 may also
have a U-rich downstream element (DSE) that regulates proximal
polyadenylation, as is found in AAV-5 (Qiu et al., 2004).
Structural modeling of rodent AAV capsids
Fig. 4A shows structural models for the AAV-2, AAV-mo.1,
and AAV-ra.1 capsids. As would be predicted from their
sequences, the AAV-mo.1 capsid is predicted to lack spikes,
while the AAV-ra.1 capsid has spikes similar in size to those on
AAV-2. There are noticeable differences in charge distributions
among these three capsids. The AAV-mo.1 capsid is predicted to
have a surface that is more serine and threonine-rich compared
to AAV-2. Instead of the basic heparin-binding site (Kern et al.,
2003; Opie et al., 2003) and acidic dead zone (Lochrie et al.,
2006) on the surface of AAV-2 (Fig. 4B), both of which are
required for in vitro transduction by AAV-2, the AAV-mo.1
capsid is predicted to have fewer acidic and basic amino acids
and more polar and uncharged amino acids at the same
positions. However, the AAV-mo.1 capsid is predicted to have a
more highly charged dimple compared to AAV-2 (Fig. 4B).
Almost every amino acid in the AAV-mo.1 capsid dimple is
predicted to be charged, whereas the AAV-2 dimple is
composed of a mixture of amino acids.
The external surface of the AAV-ra.1 capsid is predicted to be
less charged and have more asparagine and glutamine than
either the AAV-2 or the AAV-mo.1 capsid. The AAV-ra.1 capsid
is also predicted to lack a heparin-binding site and dead zone
comparable to the ones on the AAV-2 surface.
As shown in Fig. 4C, the external surfaces of the AAV-mo.1
and AAV-ra.1 capsids are predicted to be substantially different
from that of any other AAV capsid. Only about 25% of their
surface areas are expected to be identical to AAV-2. Most of the
amino acids predicted to be on the surface of the AAV-mo.1 and
AAV-ra.1 capsids that are identical to those predicted to be on
the surface of any other AAV capsids are on the cylinder,
dimple, or canyon while most of the differences are on the
plateau and spike. The dimple and canyon areas on the surface
of AAVs are predicted to be mostly inaccessible to antibodybinding, while the cylinder, plateau, and spike are predicted to
be highly accessible to antibody binding. These observations
suggest that rodent AAV capsids may be resistant to
neutralization by human antibodies.
The predicted internal surfaces of AAV-2, AAV-mo.1, and
AAV-ra.1 are shown in Fig. 4D. Based on sequence and
structural comparisons of the AAV-2 capsid with DNA-bound
forms of canine parvovirus and minute virus of mice, 24 amino
acids on the internal surface of the AAV-2 capsid are predicted
to contact the DNA (Fig. 4D, left panel). Of these 24 amino
acids 15 are identical in the AAV-mo.1 capsid sequence and 12
are identical in the AAV-ra.1 capsid sequence. Amino acids
predicted to make nonspecific contacts to the ribose and
phosphate backbone are highly conserved between AAV-2 and
the rodent capsids, whereas those predicted to contact bases are
less conserved. This suggests the nucleotide sequences required
to optimally package rodent AAV genomes may be different
from that of AAV-2.
Copy number of rodent AAV capsid genes
The copy number of AAV-mo.1 and AAV-ra.1 capsid genes
was measured in genomic DNA prepared from 4 different rat or
3 different mouse livers using Q-PCR primers and probes
specific to each capsid. The results are shown in Table 2. The
copy number of AAV mo.1 capsid gene varied from 0.0005 to
0.3 copies per cell. The copy number of AAV ra.1 capsid gene
was higher on average, varying from 0.007 to 4.5 copies per
cell. The copy number did not vary by more than 3-fold in
samples taken from different areas of a liver from the same
animal. These copy numbers are within the same range as that
found for primate and human AAVs in various tissue samples
(Gao et al., 2003). The AAV-ra.1 capsid was not detected in the
mouse liver DNA samples and the AAV-mo.1 capsid was not
detected in the rat liver DNA samples, at a sensitivity of 0.0003
copies per cell.
Production of rAAV-mo.1
The AAV-mo.1 capsid gene was cloned into an expression
plasmid in order to generate rAAV-mo.1 virions. Two vectors
were produced, rAAV-mo.1 lacZ and rAAV-mo.1 hFIX9, which
encode E. coli β-galactosidase and human factor IX transgenes,
respectively. Both the lacZ and the hFIX9 genomes had AAV-2
ITRs.
The productivity of rAAV-mo.1 lacZ and rAAV-mo.1 hFIX9
was 20% and 11% that of rAAV-2 lacZ and rAAV-2 hFIX9,
respectively. Thus, although the inside surface of the AAV-mo.1
capsid is predicted to have several differences compared to the
inside of AAV-2 (Fig. 4D), these do not appear to be significant
enough to prevent DNA packaging of AAV-2 ITR-based
genomes by the AAV-mo.1 capsid.
In vitro transduction by AAV-mo.1
As shown in Table 3, AAV-mo.1 lacZ was able to transduce 3
rodent cell lines (C6, 3T6, NIH3T3), but transduction of
Fig. 4. Structural modeling of rodent AAV capsids. (A) Comparison of predicted external surfaces of AAV-2 (left), AAV-mo.1 (middle), and AAV-ra.1 (right) capsids.
The white triangle outlines the boundary of an asymmetric structural unit. AAV capsids are composed of 60 identical asymmetric structural units. (B) External surfaces
of the asymmetric units of AAV-2 (left), AAV-mo.1 (middle), and AAV-ra.1 (right). The location of the acidic dead zone and 5 basic amino acids that are required for
heparin binding are shown on the AAV-2 asymmetric unit. Numbering is based on the AAV-2 VP1 protein. (C) Amino acids on AAV-2 (left), AAV-mo.1 (middle), and
AAV-ra.1 (right) predicted to be unique to that capsid are colored black. The location of major external surface features (cylinder, canyon, dimple, spike, plateau) is
indicated and the approximate boundaries of these features within an asymmetric unit are indicated by circular black lines. The numbers 2, 3, and 5 represent the 2-, 3-,
and 5-fold axes of symmetry, respectively. The cylinder surrounds the 5-fold axis of symmetry. The canyon surrounds the cylinder. The spike and plateau alternate
between each other and surround the 3-fold axis of symmetry. The dimple is located at the 2-fold axis of symmetry. (D) Comparison of predicted internal surfaces of the
asymmetric units of AAV-2 (left), AAV-mo.1 (middle), and AAV-ra.1 (right). The location of amino acids likely to bind DNA is shown on the AAV-2 asymmetric unit.
Numbering is based on VP1 protein. Amino acids are colored as follows: red: D, E; pink:W; brown: P; orange: S, T; yellow: C, M; dark blue: R, K; medium blue: N, Q;
light blue: F, Y; light green: H; dark green: I, L, V; gray: A; white: G.
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Table 2
Copy number of rodent AAV capsid genes in liver genomic DNA
Species Animal Copies per cell a
Rat 1 2.4 ± 0.1
2 0.007 ± 0.002
3 0.04 ± 0.03
4 4.5 ± 2.3
Mouse 1 0.3 ± 0.006
2 0.1 ± 0.09
3 0.0005 ± 0.0003
The lower limit of sensitivity was 0.0003 copies per cell.
a Mean ± SD. Each sample was measured in duplicate.
Fig. 5. Heparin binding. rAAV-2 lacZ, rAAV-5 lacZ, and rAAV-mo.1 lacZ were
incubated with heparin beads as described in Materials and methods. S,
supernatant containing AAV not bound to heparin beads. P, pellet containing
AAV bound to heparin beads. Only VP3 is shown.
75M.A. Lochrie et al. / Virology 353 (2006) 68–828 human cell lines and primary human fibroblasts was not
detectable at multiplicities of infection as high as 1 × 104 vg/
cell. Therefore, AAV-mo.1 may have an ecotropic, rodent-
specific tropism. rAAV-mo.1 lacZ was typically 1.5- to 2-fold
more infectious than rAAV-2 lacZ on rat C6 cells. The
transduction efficiency of rAAV-ra.1 lacZ on C6 and NIH3T3
cells was at least 1000-fold less than that of AAV-mo.1, and
therefore, no further experiments were done with rAAV-ra.1.
Inhibition of rAAV-mo.1 lacZ transduction by soluble heparin,
mucin, and sialic acid
Heparin binds to and inhibits AAV-2. N-acetylneuraminic
acid binds to and inhibits AAV-4 and AAV-5. To begin to
understand, the types of receptors rAAV-mo.1 may use to
infect cells heparin, mucin, and N-acetylneuraminic acid were
tested for their ability to inhibit rAAV-mo.1 transduction of
rat C6 cells. Heparin at concentrations up to 1 mg/ml, mucin
at up to 20 mg/ml, and N-acetylneuraminic acid at up to
0.2 mg/ml did not inhibit rAAV-mo.1 transduction. rAAV-
mo.1 also did not bind to heparin beads (Fig. 5), whereas
AAV-2 bound to heparin beads and AAV-5 did not, as
expected. These results confirm those predicted from the
AAV-mo.1 capsid sequence, namely that it is not likely to
bind heparin.Table 3
In vitro transduction by AAV-mo.1 lacZ
Cell name Species Type TU/1 × 109 vg a
C6 Rat Glioma 1056
3T6 Mouse Fibroblast 709
NIH3T3 Mouse Fibroblast 2500
293 Human Kidney <1
ARPE-19 Human Retinal <1
Hep3B2.1-7 Human Hepatocellular carcinoma <1
SNU182 Human Hepatocellular carcinoma <1
PLC/PRF/5 Human Hepatoma <1
HepG2 Human Hepatoma <1
HeLa Human Cervical carcinoma <1
U87/MG Human Glioma <1
Primary fibroblast Human Fibroblast <1
a TU, transducing units as determining by counting β-galactosidase
expressing cells. The lower limit of detection was 1 TU. vg, vector genomes
as determined by Q-PCR.In vitro neutralization of AAV-mo.1
As shown in Table 4, rAAV-mo.1 lacZ was resistant to
neutralization by 29 times more pooled human IgG (IVIg) than
was AAV-2. AAV-mo.1 is in a group of animal AAVs that
includes AAV-co.2 and AAV-Go.1 that are more resistant to
neutralization by human IgG than are primate-derived AAVs
such as AAV-2 and AAV-8.
In vivo transduction by AAV-mo.1
rAAV-mo.1 hFIX9 and rAAV-8 hFIX9 vectors encoding the
human factor IX gene were produced. The vectors were highly
pure as judged by SDS-PAGE (Fig. 6A) and were monomeric
(99.9–100%) as measured by dynamic light scattering.
Prior to testing rAAV-mo.1 hFIX9 vectors in vivo, they were
tested for factor IX production from rat C6 cells in vitro. rAAV-
mo.1 hFIX9 was able to mediate production of 200 or 300 ng/
ml hFIX9 at 48 or 72 h, respectively, after transduction. In
addition, sera from the SCID mice used for in vivo transduction
were tested to determine if it could inhibit transduction of C6
cells and no inhibition was observed.
After intramuscular injection of rAAV-mo.1 hFIX9 and
rAAV-8 hFIX9, serum levels of human factor IX were
undetectable (<0.02 ng/ml). However, after intravenous (tail
vein) injection of rAAV-mo.1 hFIX9 and rAAV-8 hFIX9,
comparable levels of factor IX were produced from each vector
(400–500 ng/ml) over a similar time course as shown in Fig. 6B
(for rAAV-mo.1) and 6C (for rAAV-8). Expression rose rapidly
within 1 week of injection and plateaued about 8 weeks after
injection.Table 4
In vitro neutralization of rAAV lacZ viruses by pooled, human immunoglobulin
(IVIg)
Virus a Neutralizing concentration
(mg/ml) b
rAAV-2 lacZ 0.7
rAAV-8 lacZ 9
rAAV-co.2 lacZ 19
rAAV-mo.1 lacZ 20
rAAV-Go.1 lacZ 31
a co.2, bovine-derived AAV capsid (Arbetman, personal communication) with
an amino acid sequence that is 5 amino acids different from that described by
Schmidt et al. (2004). Go.1, goat-derived AAV capsid as described by Arbetman
et al. (2005).
b Concentration of IVIg at which 50% of the virus was neutralized.
Fig. 6. In vivo transduction after intravenous delivery. (A) SDS-PAGE analysis of rAAVs. 1 × 1010 capsids of rAAV-2 empty particles or 1 × 1010 vg of rAAV-8 hFIX9
and rAAV-mo.1 hFIX9 were loaded per lane and stained with silver. (B) Human factor IX (hFIX) levels in plasma after intravenous administration of rAAV-mo.1
hFIX9. (C) Human factor IX (hFIX) levels in plasma after intravenous administration of rAAV-8 hFIX9. The lower limit of detection was 0.02 ng/ml hFIX. The normal
level of endogenous mouse FIX is 5 μg/ml.
76 M.A. Lochrie et al. / Virology 353 (2006) 68–82AAV lacZ vectors representing nine AAV serotypes were
injected into mouse eyes via a subretinal delivery route. As
shown in Fig. 7, transduction of murine ocular cells by rAAV-
mo.1 was more efficient and widespread than transduction by
rAAV-2, rAAV-3b, rAAV-4, and AAV-Go.1. It was about as
efficient and widespread as transduction by rAAV-6 and rAAV-
8. However, it was not as efficient or widespread as transduction
by rAAV-1 and rAAV-5. No blue staining was observed when
vehicle alone was injected.
Biodistribution of AAV-mo.1
After intravenous administration of rAAV-mo.1 hFIX9,
ten tissues were harvested 4 weeks after injection, and the
number of copies of the hFIX9 genome was measured. As
shown in Table 5, the highest hFIX9 copy number was
found in liver and was at least 10-fold lower in other
tissues. The copy number of hFIX9 genomes delivered by
rAAV-8 was also highest in liver and much lower in other
tissues, as has been reported by others.
Discussion
Sequences from a novel rat and mouse AAV were isolated.
Their capsid sequences are <60% identical to any other AAV
capsid, and therefore, each defines a new species of AAV. The
existence of rodent AAVs in any form (e.g., particles in
electron micrographs, contaminants of rodent adenovirus
stocks) has not been previously reported. The capsids of
AAV-mo.1 and AAV-ra.1 have several unique properties. Both
are predicted to be significantly different on their external
surfaces and to some degree on their internal surfaces,
compared to other AAVs. Regions that are variable on the
external surfaces of viruses are often involved in immune
evasion and receptor binding. Not surprisingly, AAV-mo.1was highly resistant to neutralization by human IgG. The
rAAV-mo.1 capsid did not bind heparin and was not
neutralized by soluble heparin, mucin, or N-acetylneuraminic
acid. This suggests that the receptors AAV-mo.1 uses to infect
cells may be different from those identified for other AAVs.
The rodent AAVs are taxonomically most similar to AAV-5
and AAV-Go.1. In addition, the splicing and polyadenylation of
the rodent AAV mRNAs are predicted to be most similar to that
of AAV-5 (Qiu et al., 2004). Compared to AAV-2, AAV-5
transcription is less dependent on helper virus functions. Also
the promoter in the ITR of AAV-5 is stronger than that in the
AAV-2 ITR. In the future, it may be interesting to isolate full-
length infectious clones of AAV-mo.1 and AAV-ra.1 to examine
the similarity of their gene expression patterns to that of AAV-5
in more detail. One aspect of gene expression that may be
unique to the rodent AAVs is translation initiation of VP2,
which may begin at a CUG codon. Translation initiation at CUG
codons has been previously reported for other cellular genes
(Schwab et al., 2004) but not for viruses or AAVs.
The AAV ra.1 capsid gene was not detected in 3 mouse liver
DNA samples, and the AAV mo.1 capsid gene was not detected
in 4 rat liver DNA samples. It may be that, even though rat and
mouse genes are very homologous to each other in general, their
respective AAVs have diverged substantially. Alternatively,
since we only examined liver DNA for the presence of rodent
AAV capsid genes, it could be that other rodent AAVs will be
found in other rodent tissues.
After intravenous injection into mice, rAAV-mo.1 is found
primarily in the liver and can produce high serum levels of
human factor IX. The transgene copy number and levels of
factor IX produced using AAV-mo.1 were as high as that from
AAV-8, which is considered to be one of the most efficient
AAVs that can transfer genes to the liver. After a subretinal
injection into mice, rAAV-mo.1 also resulted in efficient and
widespread transduction of murine ocular cells. In the future, it
Fig. 7. In vivo transduction after subretinal delivery. Mouse eyes were injected subretinally with 1 × 109 vector genomes of rAAV-mo.1 lacZ (top row, left panel),
rAAV-1 lacZ (top row, middle panel), rAAV-2 lacZ (top row, right panel), rAAV-3b lacZ (middle row, left panel), rAAV-4 lacZ (middle row, middle panel), rAAV-5
lacZ (middle row, right panel), rAAV-6 lacZ (bottom row, left panel), rAAV-8 lacZ (bottom row, middle panel), or rAAV-Go.1 lacZ (bottom row, right panel). Six
weeks after injection, whole eyes were fixed and stained for β-galactosidase activity.
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were transduced in the subretinal space. Based on the limited in
vitro transduction experiments reported here, the tropism of
AAV-mo.1 may be restricted to rodents, which may limit its use
for human gene transfer. As suggested above, it is possible
AAV-mo.1 uses receptors to enter cells that are different fromTable 5
Biodistribution after intravenous delivery
Copies of hFIX9 genomes per cell aTissue
rAAV-mo.1 hFIX9 rAAV-8 hFIX9
Liver 0.4 ± 0.03 0.9 ± 0.65
Lung 0.03 ± 0.04 <0.0008
Muscle 0.005 ± 0.006 0.001 ± 0.0004
Kidney 0.004 ± 0.0005 0.0008 ± 0.0003
Testis 0.003 ± 0.003 nd
Intestine 0.002 ± 0.0003 nd
Heart <0.0008 0.001 ± 0.0004
Spleen <0.0008 <0.0008
Eye <0.0008 nd
Brain <0.0008 <0.0008
a The number of cells was estimated from the amount of genomic DNA used
in the hFIX9 Q-PCR, using a conversion factor of 1.5 × 105 cells per 500 ng
genomic DNA. 0.0008 copies per cell were the lower limit of detection. Results
are the average ± SD from 2 animals. nd, not determined.the receptors that other known AAVs utilize. If AAV-mo.1
transduces only rodent cells it would be the first example of an
AAV that does not have a broad species tropism. Transduction
of more human cell lines, other primary human cells, or in vivo
gene transfer to a primate may identify primate cells that are
transduced by AAV-mo.1. Alternatively it may be possible to
mutate and select rodent AAV capsids that are capable of
transducing humans cells using recently described methods
(Maheshri et al., 2006; Muller et al., 2003; Perabo et al., 2003).
Although AAV-mo.1 did not transduce the human cell lines
we analyzed, it may be useful for gene transfer studies in rats
and mice. For example, it may be useful for delivering
exogenous genes to generate or treat disease models. It may
also be useful for deleting or substituting genes in rodents.
Recently, AAV-2 has been shown to be more efficient than
plasmids for altering endogenous mouse genes (Kohli et al.,
2004). AAV-mo.1 could be more efficient than AAV-2 for this
purpose.
The AAV-ra.1 vector transduced rodent cells poorly in vitro.
Many AAVs that transduce poorly in vitro can transduce
efficiently in vivo (e.g., AAV-1, AAV-8). Therefore, in the
future, it will of interest to explore the in vivo transduction
properties of AAV-ra.1. Alternatively, the poor transduction
efficiency of AAV-ra.1 may be a result of the fact that we cannot
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naturally occurring.
The existence of rodent AAVs and aspects of their biology
that we did not study may have implications for experiments
that deliver the genomes of other AAVs into rodents. If
endogenous rodent AAV rep is expressed, then could it act on
the ITRs of exogenous AAVs to result in site-specific
chromosomal integration? AAV-mo.1 capsids can package
AAV-2 ITR-based genomes. Could an AAV-2 based genome
be packaged by endogenous rodent AAV capsids after in vivo
gene transfer and then spread to tissues that nonrodent AAVs do
not normally transduce? Most AAVs are presumed to require a
helper virus for efficient replication, maintenance, and trans-
mission. Several AAVs have been isolated from adenovirus or
herpes virus stocks and hence the identity of their helper virus is
known. Since the rodent AAVs reported here were isolated from
genomic DNA the nature of their helper virus, if any, is not
known. In fact, they could be autonomous parvoviruses that are
able to replicate without a helper virus.
To summarize, sequences were isolated that define two new
species of AAVs from rat and mouse. Each has several unique
properties compared to other AAVs. The AAV-mo.1 capsid can
mediate efficient transduction of rodent cells in vitro and in vivo
and hence could be useful as an experimental tool for gene
transfer in rodents.
Materials and methods
Materials
HepG2, HeLa, 293, C6, 3T6, ARPE-19, Hep3B2.1-7,
SNU182, U87/MG, NIH3T3, and PLC/PRF/5 cells were
obtained from the American Type Culture Collection. Primary
human fibroblasts were obtained from Cambrex. Etoposide
was obtained from Calbiochem and dissolved in DMSO to a
concentration of 20 mM. Pooled, purified human IgG
(Panglobulin), called IVIg, was purchased from the American
Red Cross and dissolved in water to a concentration of
100 mg/ml. All oligonucleotide primers for Q-PCR and DNA
sequencing were obtained from Operon Biotechnologies. Q-
PCR probes were obtained from Applied Biosystems.
Enzymes used for PCR included rTth DNA polymerase
(Perkin Elmer), Taq (Roche Molecular Biochemicals), and
Herculase (Stratagene). PCR products were cloned using the
TA kit (Invitrogen), the Perfectly Blunt kit (Novagen), or the
PCR-Script Amp kit (Stratagene), depending on which
enzymes were used for PCR amplification. Sequencing was
performed by Elim Biopharmaceuticals, Inc. DNA sequences
were aligned, analyzed, percent identities were calculated, and
taxonomic trees were generated using Vector NTI, version
8 software (Invitrogen).
Isolation of rodent AAV capsid genes
Rats and mice were obtained from local pet stores. Rat
and mouse liver genomic DNA, prepared using a DNeasy
tissue kit (QIAGEN), was subjected to PCR using primerAA55 (5′-GTGCCCTTCTACGGCTGCGTCAACTGGAC-
CAATGAGAACTTTCC-3′) and AA56 (5′-GGAATCGCA-
ATGCCAATTTCCTGAGGCATTACCCACTCC-3′). rTth
DNA polymerase was used, and the PCR conditions were
denaturation at 94 °C. for 15 s, annealing at 45 °C. for
30 s, and extension at 72 °C. for 2 min for 35 cycles. All
reactions were performed in 50 μl using an Eppendorf
Mastercycler Gradient thermocycler. Each reaction mixture
contained 200 ng of genomic DNA, 1 μM each oligonu-
cleotide primer, 1 mM Mn(OAc)2, 200 μM deoxynucleoside,
and 1.0 unit of rTth polymerase, XL (Applied Biosystems)
in 1× XL Buffer II. Ampliwax PCR gem 100 beads
(Applied Biosystems) were used to enable a hot start PCR.
Using these conditions, a 1.5 kbp DNA that contains about
800 bp of the C-terminus of the rep gene and about 700 bp
of the N-terminus of the capsid gene was isolated. To isolate
the rest of the mouse AAV (AAV-mo.1) capsid gene and
most of the rest of the rat AAV (AAV-ra.1) capsid gene,
genome walking was performed using the DNA Walking
SpeedUp kit (Seegene, Inc.) which utilizes inosine contain-
ing, annealing controlled primers (Hwang et al., 2003; Kim
et al., 2004).
In the first genome walk three nested AAV-mo.1 target-
specific primers (TSP) located 5′ to the AAV-mo.1 capsid
gene (mTSP1: 5′-AGAAATGTACGCTGGACTC-3′, mTSP2:
5′-CGTGGTTGGAGGGGANCC-3′, mTSP3: 5′-GGGAGT-
GTCCCGATTCAAATAA-3′) or three nested AAV-ra.1 spe-
cific primers located 5′ to the AAV-ra.1 capsid gene (rTSP1:
5′-CCTCGGTAGTCCACGAC-3′, rTSP2: 5′-GGGGACAC-
TGTGTTCGATTT-3′, rTSP3:, 5′-GGAGTGCCCCGATTCT-
AATAAA-3′) were used with three primers (DW-ACP1-4,
DW-ACP-N, and Universal Primer) from the DNA Walking
SpeedUp kit in 3 separate polymerase chain reactions, exactly
according to the manufacturer's instructions. In the first
polymerase chain reaction, mTSP1 or rTSP1 was used with
DW-ACP-1, DW-ACP-2, DW-ACP-3, or DW-ACP-4 in four
separate PCR reactions. In the second polymerase chain
reaction, an aliquot of each of the four first reactions was
amplified with mTSP2 or rTSP2 and DW-ACP-N. In the third
polymerase chain reaction, an aliquot of the second reaction was
amplified with mTSP3 or rTSP3 and the Universal Primer. The
resulting PCR products were gel purified and subjected to
sequencing using the Universal Primer. PCR products that had
homology to AAV capsid sequences were subcloned and
sequenced on both strands to obtain high quality sequences
suitable for designing primers for the next walking step.
Subsequent walking steps were done in a similar fashion.
For the second walk, the sequences of the three primers from
the AAV-mo.1 capsid sequence were mTSP4 (5′-ACCTTGATGT-
CACTTCGAG-3′), mTSP5 (5′-TACCTATCAAAAAGGAGTT-
CAC-3′), and mTSP6 (5′-TGCCCGAACAAGAGCGCAAC-3′)
and the sequences of the three primers from the AAV-ra.1 capsid
sequence were rTSP4 (5′-GGAACAACTTTGAATTTACCT-3′),
rTSP5 (5′-TCGCCCCCTGTCAGAACC-3′), and rTSP6 (5′-
CAAGCTGAGCAATCCCCTGG-3′).
For the third walk on the AAV-mo.1 capsid gene, the
sequences of the three 5′ primers were mTSP7 (5′-
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CACACCTGTTCC-3′), and mTSP9, 5′-GTTCCGGCTGA-
CCCCCCC-3′). The 3′ primers targeted polyadenylation
signals and were designed in a way that was similar to the
annealing controlled primers. The four 3′ primers for the first
step had the sequence 5′-TCACAGAAGTATGCCAAGC-
GAIIIII [A, C, G, T] TTTATT-3′ and were used in 4 separate
reactions along with mTSP7. Then an aliquot of each of those
reactions was amplified with mTSP8 and a 3′ primer with the
sequence 5′-TCACAGAAGTATGCCAAGCGAIIIIINTT-
TATT-3′ As before, for the third PCR, mTSP9 and the
Universal primer (5′-TCACAGAAGTATGCCAAGCGA-3′)
were used to amplify an aliquot of the second PCR step.
For the third walk on the AAV-ra.1 capsid gene, two 5′ primers
were designed from the AAV-ra.1 capsid sequence, rTSP7 (5′-
GGATGTCTCTACCGCCC-3′) and rTSP8 (5′-GACACGACT-
CAGTATAACATC-3′). Two 3′ primers were designed to
hybridize to the C-terminal sequences of 140 known AAV
capsids. A 47-mer with the sequence 5′-GTAAAACGACGGC-
CAGTTTAIGGIGGICKIGTIGGGTAICKNGTNCC-3′ or a 38-
mer with the sequence 5′-GTAAAACGACGGCCAGTTTAIG-
GIKKIYKISKIGKGTA-3′ was used. The underlined sequence
corresponds to the 5′ universal tag (M13 forward primer), the
TTA corresponds to the TAA stop codon found after all AAV
capsids except 2 snake AAVs, and the 3′ ends of the primers
correspond to sequences encoding the last 6 or 9 amino acids of
AAV capsid sequences. In the first PCR, rTSP7 was used with
both 3′ primers. In the second PCR step, rTSP8 was used with the
M13 forward primer (5′-GTAAAACGACGGCCAGT-3′).
Quantitative polymerase chain reactions
To assess the copy number of AAV-mo.1 and AAV-ra.1
capsid genes in liver genomic DNA, Q-PCR primers and probes
were designed that are located in the N-terminus of capsid. The
sequences of the primers used for amplification of the AAV-
mo.1 capsid gene are 5′-GAGGCGGGAGACAATCCCT-3′
and 5′-TTCAACGCCTCCTGGAACTC-3′. The sequence of
the AAV-mo.1 capsid gene probe is: 5′-6-FAM-CCTCAAG-
TACAACCACGCCGACCG-TAMRA-3′). An oligonucleotide
(5′-GCTTGAGGCGGGAGACAATCCCTACCTCAAGTA-
CAACCACGCCGACCGCGAGTTCCAGGAGGCGTT-
GAAGGC-3′) containing the sequences of the AAV-mo.1
capsid probes and primers was used for a copy number standard.
The sequences of the primers used for amplification of the AAV-
ra.1 capsid gene are: 5′-TTGAGAGCGGTGAGAATCCTTAC-
3′ and 5′-TCCTCCGCGAGGTCCTTC-3′. The sequence of the
AAV-ra.1 capsid gene probe is 5′-6-FAM-TCACTTTTAAT-
CACGCTGATCGGCAGCT-TAMRA-3′). An oligonucleotide
(5′-GCTCTGCTTGAGAGCGGTGAGAATCCTTACCT-
CACTTTTAATCACGCTGATCGGCAGCTGCAGAAG-
GACCTCGCGGAGGACCGC-3′) containing the sequences of
the AAV-ra.1 capsid probes and primers was used for a copy
number standard.
Quantitative polymerase chain reaction (Q-PCR) was also
used to assess DNA packaging by rAAV lacZ and rAAV hFIX9
vectors. Virions were diluted 100-fold and digested withDNAse I to remove any plasmid, used in the transfection to
produce the vectors, which might result in a false positive
signal. The sequences of the primers used for amplification of
the lacZ gene are 5′-TGCCACTCGCTTTAATGAT-3′ and 5′-
TCGCCGCACATCTGAACTT-3′. The sequence of the lacZ
probe is: 5′-6-FAM-AGCCTCCAGTACAGCGCGGCTGA-
TAMRA-3′. The sequences of the primers used for amplifica-
tion of the human factor IX gene are 5′-ACCAGCAGTGC-
CATTTCCA-3′ and 5′-GAATTGACCTGGTTTGGCATCT-3′.
The sequence of the hFIX probe is 5′-6-FAM-TTGGATAA-
CATCACTCAAAGCACCCAATCA-TAMRA-3′.
All amplifications were done using an Applied Biosystems
model 7000 or 7700 Sequence Detection System using the
standard amplification program. A standard curve was con-
structed using 4-fold dilutions of linearized plasmids
(pVmLacZ or pAAV-hFIX9) ranging from a copy number of
61 to 1,000,000. The copy number of packaged genomes in
each sample was calculated from the Ct values obtained from
amplification plots using the Prism Sequence Detection System
software.
Structural modeling of capsids
Coordinates for the monomeric AAV-2 capsid protein
(Protein Database ID: 1LP3) were obtained from the Virus
Particle Explorer (VIPER) website (http://mmtsb1.scripps.edu/
viper/). AAV-mo.1 and AAV-ra.1 capsid amino acid sequences
were fit into the monomeric AAV-2 capsid structure using Swiss
PDB Viewer, version 3.7b1 (http://www.expasy.org/spdbv/).
Coordinates for entire capsids, containing 60 monomers, were
generated using the Oligomer Generator tool at the VIPER
website. Those coordinates were rendered into space filling
models using Chime (MDL Information Systems, Inc.; http://
www.umass.edu/microbio/chime/getchime.htm) installed as a
Netscape browser plug-in. Asymmetric structural units were
generated using Swiss PDBViewer as follows. Coordinates for a
structure that contains the 6 capsomeres that contribute to an
asymmetric structural unit were generated at VIPER. Extraneous
amino acids within those 6-mers that are not in a single
asymmetric structural unit were deleted using Swiss PDB
Viewer. Asymmetric structural units were rendered as space
filling models and colored using Swiss PDB Viewer.
The DNA-binding domains on the internal surface of the
AAV-2 capsid were predicted by structural and sequence
alignments with parvoviruses (canine parvovirus, minute virus
of mice) for which high resolution X-ray crystal structures of
DNA-bound forms of the capsids are known. Two DNA-bound
forms of the canine parvovirus (Protein Database ID: 4DPV,
1IJS) and two DNA-bound forms of the minute virus of mice
(Protein Database ID: 1MVM, 1Z1C) are known. Amino acids
in capsid closer than 3 Å to the DNA in these structures were
considered to be potentially in contact with the DNA.
rAAV lacZ preparation
rAAV containing the E. coli lacZ (β-galactosidase) gene
were prepared in 293 cells using a calcium phosphate-
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al., 1998). The three plasmids used in the transfection were
pladeno5 (which supplies adenovirus helper genes E2a, E4,
VA I, and VA II), pVmlacZ (which provides the lacZ gene
under the control of a CMV promoter and flanked by AAV-2
inverted terminal repeats), and pHLP19 (which supplies AAV-
2 rep and cap genes) or a pHLP19 derivative with the AAV-
mo.1, AAV-ra.1, AAV-8, AAV-co.2, or AAV-Go.1 capsid
coding region substituted directly for the AAV-2 capsid
coding region. The AAV-mo.1 and AAV-ra.1 capsid coding
regions were amplified using Herculase DNA polymerase.
pLadeno5 and pVmLacZ are described in U.S. Patent
#6,004,797. pHLP19 is described in U.S. Patent #6,841,357.
Transfection was for 6 h, the DNA mixture was removed
from the cells, fresh cell culture medium without fetal calf
serum was provided, and the cells were incubated for an
additional 66 h. After transfection the cells were lysed by
microfluidization. The cell lysate was clarified by filtration,
treated with Benzonase and RNAse A, and AAV was
precipitated with 8% polyethylene glycol, 620 mM NaCl
for 2 h at 4 °C. The AAV was pelleted, then resuspended in
50 mM HEPES, pH 8.0, 150 mM NaCl, 25 mM EDTA, 1%
N-lauroyl sarcosinate at 37 °C. for 1 h. DNA-containing
virions were purified from non-DNA-containing virions using
2 successive CsCl gradients. The first gradient was a step
gradient with 12 ml 1.30 g/ml CsCl and 6 ml 1.55 g/ml CsCl.
The lower, DNA-containing band was collected and centri-
fuged on a continuous gradient initially containing 1.372 g/ml
CsCl. The DNA-containing band was collected, and the CsCl
was removed by dialysis against Tris-buffered saline (TBS),
pH 8.0, 0.001% Pluronic F-68. The purity of the vector was
assessed by SDS-PAGE followed by silver staining (Silver
Express, Invitrogen) and by dynamic light scattering (model
DynaPro 99, Protein Solutions).
Heparin-binding assay
Binding of cesium chloride gradient-purified viruses was
performed by mixing 10 μl (5 × 1010 vector genomes) of rAAV-
2 lacZ, rAAV-5 lacZ, and rAAV-mo.1 lacZ with 10 μl of a 50%
slurry of heparin beads. The heparin beads (Ceramic Hyper-DM
Hydrogel-Heparin, Biosepra) are 80 μm in diameter and have
1000 Å pores. They were washed thoroughly in TBS prior to
use. The beads and virions were incubated at 37 °C. for 60 min.
The beads were pelleted at 10,000×g for 30 s. The supernatant
containing unbound virions was saved. The beads were washed
3 times with 300 μl TBS and pelleted at 10,000×g for 30 s. The
supernatants were combined and precipitated with 10%
trichloroacetic acid. Bound and unbound virions were dena-
tured in 0.1% SDS at 80 °C for 5 min, fractionated by SDS-
PAGE, and then detected by Western blotting as follows.
Proteins were electrophoretically blotted onto nylon membranes
(Hybond-P, GE Healthcare), probed with an anti-AAV capsid
antibody (monoclonal clone B1, Maine Biotechnology Ser-
vices) at a dilution of 1:20, and then probed with a sheep anti-
mouse antibody coupled to horseradish peroxidase (GE
Healthcare) at a dilution of 1:12,000. Antibody-bound proteinswere detected using the ECL Plus detection system (GE
Healthcare) followed by exposure to X-ray film (Biomax MR,
Kodak) for 5 min. Images of the X-ray film were taken using an
AlphaImager 3300 (Alpha Innotech).
In vitro transduction by rAAV-mo.1 lacZ
Cells were plated in 24-well dishes at 1 × 105 cells per well in
1 ml of media. After 24 h, 10-fold dilutions of rAAV-mo.1 lacZ
virus, beginning with 1 × 109 vg, were added to the cells along
with etoposide to enhance transduction. Three-fold dilutions of
etoposide ranging from 0.1 to 100 μM were used initially to
determine the optimal amount of etoposide which produced the
maximal amount of transduction on a given cell. After 24 h at
37 °C the cells were fixed and stained for β-galactosidase
activity for 24 h at 37 °C. The total number of blue cells in each
well was counted.
In vitro transduction by rAAV-mo.1 hFIX9
The hFIX9 vector contains AAV-2 ITRs, a CMV immediate
early enhancer and promoter, the first intron of the human factor
IX gene, the human factor IX coding region, and the SV40 late
polyadenylation signal. rAAV-mo.1 hFIX9 was produced,
purified, and characterized as described above for the lacZ
vector. It was used to transduce rat C6 cells at a multiplicity of
infection of 1e5 vg/cell. A factor IX ELISA kit (Affinity
Biologicals) was used to assess factor IX production from rat C6
cells 48 or 72 h after transduction.
Inhibition of rAAV-mo.1 lacZ transduction by soluble heparin,
mucin, and N-acetylneuraminic acid
Synthetic N-acetylneuraminic acid (Sigma, catalog #A-
0812) was dissolved at a concentration of 30 mg/ml in PBS
and the pH was adjusted to 7.2 with sodium hydroxide. Bovine
submaxillary mucin, type I-S (Sigma catalog #M-3895), was
dissolved in PBS at a concentration of 20 mg/ml. Porcine
intestinal heparin with an average molecular weight of 3000
(Sigma catalog #H-3400) was dissolved in PBS at a
concentration of 125 mg/ml. These inhibitors were diluted in
3-fold increments ranging from 1 to 1000 μg/ml heparin, 0.2 to
200 μg/ml N-acetylneuraminic acid, or 0.02 to 20 mg/ml mucin.
C6 cells (3 × 104 per well) were plated in 0.1 ml media on a 96-
well plate. Fifteen microliters (1 × 109 vg) rAAV-2 lacZ, rAAV-
5 lacZ, or rAAV-mo.1 lacZ was mixed with 15 μl of an inhibitor.
The virus and inhibitors were incubated at 37 °C for 60 min, and
then 15 μl of the mixtures was added to the cells and mixed with
the media. Etoposide was added to a final concentration of
20 μM and incubation continued at 37 °C for 24 h. The cells
were stained for β-galactosidase activity, and the number of
blue cells in the entire well was counted.
In vitro neutralization assay
C6 cells (1 × 105 per well) were plated in 24-well dishes for
24 h at 37 °C. Two-fold dilutions of IVIg were made in Eagle's
81M.A. Lochrie et al. / Virology 353 (2006) 68–82MEM, 0.1% BSA. rAAV lacZ virus was diluted to 1 × 109
vector genomes/ml in Eagle's MEM, 0.1% BSA. Equal
volumes (15 μl) of each virus and IVIg were mixed and
incubated at 37 °C for 1 h. Half of each reaction was added to
the cells along with 20 μM etoposide. After 24 h at 37 °C, the
cells were fixed and stained for β-galactosidase activity for 24 h
at 37 °C. The average number of blue cells in four random
microscopic fields was determined. The percent neutralization
of transduction was plotted against the antibody concentration.
A 4-parameter logistic equation was fit to the data (Sigma Plot)
to determine the IVIg concentration at which 50% of the virus
was neutralized.
In vivo transduction
All mice were treated humanely according to recommenda-
tions of the Avigen Institutional Animal Care and Use
Committee or the Association for Research in Vision and
Ophthalmology statement on the use of animals in research. For
intramuscular injections, male SCID mice (15–25 g, cBySmn.
CB17-Prkdcscid, The Jackson Laboratory) were injected with
2 × 1011 vector genomes in 2 sites in the quadriceps. For
intravenous injections, male SCID mice were injected via the
tail vein with 5 × 1011 vector genomes. Retro-orbital blood was
collected at 1, 2, and 4 weeks (5 mice per time point) and at
8 weeks (3 mice) after injection. Circulating plasma concentra-
tions of human factor IX were measured in duplicate using the
FIX-EIA ELISA kit (Affinity Biologicals) which does not
detect mouse factor IX.
Subretinal injections were done in 4- to 6-week-old Balb/C
mice (Charles River) with a Harvard pump apparatus and pulled
glass micropipettes as previously described (Kachi et al., 2005;
Mori et al., 2001). Micropipettes were calibrated to deliver 1 μl
of vehicle or 1 μl of AAV vector (1 × 109 vector genomes) upon
depression of a foot switch. Injections were performed using a
condensing lens system on a dissecting microscope, which
allowed visualization of the retina during the injection. Mice
were anesthetized, and their pupils were dilated. Under a
dissecting microscope, the micropipette was passed through the
sclera posterior to the limbus and was positioned just above the
retina. Depression of the foot switch caused a jet of injection
fluid to penetrate the retina. This technique is atraumatic and
allows direct visual confirmation that the injection was
successful, due to the appearance of a small retinal detachment.
The fluid is rapidly absorbed and the retina reattaches, resulting
in no damage to the retina. Six weeks after injection, the mice
were euthanized, eyes were fixed in 2% paraformaldehyde,
0.2% glutaraldehyde in PBS for 1 h, and then rinsed twice in
PBS. Fixed eyes were incubated in X-gal solution for 6 h,
incubated in 4% paraformaldehyde in PBS for 30 min, and then
rinsed twice in PBS. Stained eyes were photographed with a
Nikon Digital Still Camera (model DXM1200).
In vivo biodistribution of AAV vectors
For biodistribution analyses, mice (2 per group) were
sacrificed and the organs were collected 4 weeks afterintravenous injection of rAAV hFIX9 vectors. Genomic DNA
was prepared using a DNeasy tissue kit (QIAGEN). Q-PCR was
used to measure hFIX9 DNA, as described above, using 500 ng
genomic DNA.
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